Therapeutic combinations are described. The combinations comprise: (a) a 5- hydroxytryptamine 2C (5-HT2C) receptor agonist, or a pharmaceutically acceptable salt thereof; and (b) a triptan, or a pharmaceutically acceptable salt thereof. The combinations may be used for the treatment of disorders that can be treated by agonism of 5-HT2C receptors, such as obesity and type 2 diabetes.